Model Name
Staphylococcus aureus (Smith, ATCC 19636), Thigh Infection Model CFU/g

Item Number
608050

Introduction
This assay assesses the antimicrobial efficacy of test articles in a thigh muscle infection model. The microbial counts in tissue are measured. Staphylococcus aureus is a common cause of skin infections as well as serious life threatening diseases such as pneumonia, osteomyelitis, endocarditis, bacteremia and sepsis.

Procedure Summary
Groups of 5 neutropenic mice are used. Animals are intramuscularly inoculated with pathogen suspension then test articles or vehicle are administered at time points after inoculation. (Doses may be administered IV, SC, PO, IM, IP or by IV infusion.) At 24 hr after the first treatment, animals are humanely euthanized and tissue is aseptically removed. Tissue is homogenized and pathogen counts are determined by plating to agar medium. Pathogen counts from treatment groups are compared to vehicle groups and the significance of an effect is determined.

Turnaround Time(s)
5 weeks from sample receipt

Literature

Optional Services
Analysis of cytokines (with Luminex) and PK exposure can be performed upon request.

Related Assay(s)  (Item # - Assay Name - Species)
606000* - Staphylococcus aureus (Smith, ATCC 19636) MIC - Bacteria
608070 - Staphylococcus aureus (Smith, ATCC 19636), Dermal Infection - Mouse
608010 - Staphylococcus aureus (Smith, ATCC 19636), Peritonitis, LD90-100 - Mouse
*provided by partner lab Eurofins Pharma Discovery Services

Modified Protocols
We will readily accommodate client-specified alterations.

Laboratory
These assays are performed at our AAALAC accredited BSL2 laboratory in Taipei, Taiwan.

Animal Welfare
All aspects of this work is performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

Reference Compound(s)
Ciprofloxacin

For current details about our Company address and contact information, please reference our website http://www.pharmacologydiscoveryservices.com/company-info/
#608050 *Staphylococcus aureus* (Smith, ATCC 19636) Thigh Infection Model CFU/g Ciprofloxacin (CIP) Treatment

For current details about our Company address and contact information, please reference our website [http://www.pharmacologydiscoveryservices.com/company-info/](http://www.pharmacologydiscoveryservices.com/company-info/)

Last Modified: November 20, 2017